Samsung Bioepis notches European Commission nod for Remicade biosim

Spotlight

Incheon-based Samsung Bioepis has won approval from the European Commission for its biosimilar of Remicade, marking its second anti-TNF-α therapy in the region.

The biosimilar of infliximab, dubbed Flixabi, is indicated to treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, according to a press release from Samsung Bioepis.

Last week, the company said the U.S. FDA had accepted its biosimilar candidate of Johnson & Johnson's ($JNJ) Remicade for approval review.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

In April, the candidate won a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. It is now sold in Korea as Renflexis.

“With this approval, we are taking another important step in broadening affordable, high-quality biologic treatment options across Europe,” said Christopher Hansung Ko, president and CEO of Samsung Bioepis.

The European Commission approval opens markets in each of the 28 European Union member states as well as the European Economic Area, which includes Norway, Iceland and Liechtenstein for Samsung Bioepis, a joint venture between majority partner South Korea's Samsung Biologics and Biogen ($BIIB).

Biogen will handle marketing in the region, Samsung Bioepis noted in the release.

The therapy, designated in-house as SB2, is one of 6 biosimilar candidates for the company either approved in regulated markets such as its biosim for Pfizer ($PFE)/Amgen's ($AMGN) Enbrel (etanercept), sold as Benepali in Europe, or on the regulatory pathway.

The other candidates are biosimilars of Sanofi's ($SNY) blockbuster insulin Lantus (insulin glargine), AbbVie's ($ABBV) autoimmune treatment Humira (adalimumab), Roche's ($RHHBY) breast cancer drug Herceptin (trastuzumab) and its multicancer drug Avastin (bevacizumab)--with another 7 molecules in early stages.

- here's the Samsung Bioepis website

Suggested Articles

It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.

After a longer follow-up of 25 months, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC.

Novartis pivots Shanghai R&D from discovery to development. BeiGene nabs FDA nod for BTK inhibitor Brukinsa. FDA clears Shionogi's antibiotic Fetroja.